These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Low-dose tumour necrosis factor-alpha (TNF-alpha) and melphalan in hyperthermic isolated limb perfusion. Results from a pilot study performed in the United Kingdom. Hill S; Thomas JM Melanoma Res; 1994 Mar; 4 Suppl 1():31-4. PubMed ID: 8038593 [TBL] [Abstract][Full Text] [Related]
11. Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response. Hoving S; Seynhaeve AL; van Tiel ST; aan de Wiel-Ambagtsheer G; de Bruijn EA; Eggermont AM; ten Hagen TL Anticancer Drugs; 2006 Sep; 17(8):949-59. PubMed ID: 16940805 [TBL] [Abstract][Full Text] [Related]
12. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma. Hayes AJ; Neuhaus SJ; Clark MA; Thomas JM Ann Surg Oncol; 2007 Jan; 14(1):230-8. PubMed ID: 17066234 [TBL] [Abstract][Full Text] [Related]
13. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients. Cherix S; Speiser M; Matter M; Raffoul W; Liénard D; Theumann N; Mouhsine E; Mirimanoff RO; Leyvraz S; Lejeune FJ; Leyvraz PF J Surg Oncol; 2008 Sep; 98(3):148-55. PubMed ID: 18668638 [TBL] [Abstract][Full Text] [Related]
14. TNF-based isolated limb perfusion in unresectable extremity desmoid tumours. Grünhagen DJ; de Wilt JH; Verhoef C; van Geel AN; Eggermont AM Eur J Surg Oncol; 2005 Oct; 31(8):912-6. PubMed ID: 16098709 [TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats. Hoving S; Brunstein F; aan de Wiel-Ambagtsheer G; van Tiel ST; de Boeck G; de Bruijn EA; Eggermont AM; ten Hagen TL Cancer Res; 2005 May; 65(10):4300-8. PubMed ID: 15899822 [TBL] [Abstract][Full Text] [Related]
16. Administration of high-dose tumor necrosis factor alpha by isolation perfusion of the limbs. Rationale and results. Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Rosenkaimer F; Gérain J; Klaase J; Kroon B; Vanderveken J; Schmitz P J Infus Chemother; 1995; 5(2):73-81. PubMed ID: 8521239 [TBL] [Abstract][Full Text] [Related]
17. [Hyperthermic isolation perfusion of the extremities in malignant melanomas and soft tissue sarcomas]. Tonak J; Hohenberger W; Göhl J Chirurg; 1984 Aug; 55(8):499-504. PubMed ID: 6488994 [No Abstract] [Full Text] [Related]
18. Doxorubicin in isolation limb perfusion in the treatment of advanced limb soft tissue sarcoma. Di Filippo F; Garinei R; Anzà M; Cavaliere F; Giannarelli D; Cagol PP; Rossi CR; Santinami M; Deraco M; Botti C; Perri P; Di Filippo S; Piarulli L; Bruno P J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):81-7. PubMed ID: 16767912 [TBL] [Abstract][Full Text] [Related]
19. TNF-based isolated limb perfusion: a decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas. Grünhagen DJ; Brunstein F; ten Hagen TL; van Geel AN; de Wilt JH; Eggermont AM Cancer Treat Res; 2004; 120():65-79. PubMed ID: 15217218 [No Abstract] [Full Text] [Related]
20. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in patients with locally advanced soft tissue sarcomas: treatment response and clinical outcome related to changes in proliferation and apoptosis. Plaat BE; Molenaar WM; Mastik MF; Koudstaal J; van den Berg E; Koops HS; Hoekstra HJ Clin Cancer Res; 1999 Jul; 5(7):1650-7. PubMed ID: 10430064 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]